FLI1 Antibody

FLI1, a member of the ETS family of transcription factors, plays a crucial role in various biological processes, including hematopoiesis, angiogenesis, and development. Research has revealed its involvement in a range of physiological and pathological conditions, particularly in cancer and vascular disorders.

Here are some key insights from scientific literature:

1. FLI1 deficiency in endothelial cells contributes to the development of vasculopathy in systemic sclerosis (SSc), promoting migration, proliferation, and cell survival while inhibiting tube formation. This suggests FLI1 deficiency plays a role in both proliferative obliterative vasculopathy (occlusion of arterioles and small arteries) and destructive vasculopathy (loss of small vessels) characteristic of SSc vasculopathy. (PMID: 28370536)
2. In hepatocellular carcinoma (HCC), FLI1 acts as an oncogene, promoting tumor growth and metastasis by modulating the matrix metalloproteinase (MMP)2 signaling pathway. (PMID: 29138848)
3. Reduced serum levels of leukemia inhibitory factor (LIF) are associated with vasculopathy in SSc, and FLI1 deficiency may contribute to the inhibition of LIF-dependent biological effects on SSc endothelial cells by suppressing the expression of LIF, LIF receptor, and gp130. (PMID: 29038846)
4. Both mouse and human FLI1 genes are regulated by Ets factors in T cells. (PMID: 19829305)
5. In a Fli1-producing erythroleukemia cell line, Spi1/PU.1 expression resulted in increased proliferation through activation of growth-promoting proteins MAPK, AKT, cMYC, and JAK2. (PMID: 28586009)
6. CXCL6 expression is upregulated by FLI1 deficiency in fibroblasts and endothelial cells, potentially contributing to the development of fibrosis and vasculopathy in the skin, lung, and heart of systemic sclerosis. (PMID: 28507181)
7. FLI1 and CD13 have been identified as important mediators of resistance to BRAF inhibition, offering potential as drug targets in BRAF inhibitor-refractory melanoma. (PMID: 29048432)
8. FLI1 has been identified as a significant driving factor in small cell lung cancer (SCLC) tumor growth through the miR-17-92 pathway, making it a potential therapeutic target for SCLC treatment. (PMID: 28410216)
9. Two novel FLI1 variants (c.1010G>A and c.1033A>G) have been identified as responsible for macrothrombocytopenia, providing insights into the phenotype, pathophysiology, and diagnosis of FLI1 variant-associated thrombocytopenia. (PMID: 28255014)
10. miR-145 acts as a tumor suppressor by directly reducing FLI-1 expression, highlighting the importance of the miR-145/FLI-1 pathway in osteosarcoma tumor progression. (PMID: 27304058)
11. Research has confirmed the central role of FLI1 in regulating vascular homeostasis and identified it as a key regulator of angiogenesis by toll-like receptors (TLRs). (PMID: 29141862)
12. In American cutaneous leishmaniasis caused by Leishmania braziliensis infection, MMP1 is regulated by factors other than FLI1, and IL-6's influence on MMP1 is independent of its effect on FLI1. (PMID: 28119029)
13. Epithelial FLI1 deficiency may be involved in systemic autoimmunity and selective organ fibrosis in systemic sclerosis (SSc). (PMID: 28232470)
14. FLI1 expression varies across different subtypes of non-small cell lung cancer (NSCLC) and is correlated with clinicopathologic parameters and poorer prognosis. (PMID: 26317314)
15. FLI1 and MMP9 occupy different positions in prostate cancer compared to normal tissue and prostate hyperplasia, while MMP2 is repositioned in both prostate cancer and hyperplasia. (PMID: 26564800)
16. FLI1 promoter hypermethylation is associated with colorectal cancer. (PMID: 25472652)
17. Concurrent exogenous expression of three transcription factors, GATA1, FLI1, and TAL1, enables large-scale production of megakaryocytes from human pluripotent stem cells. (PMID: 27052461)
18. FLI1 has been identified as a clinically and functionally important target gene of metastasis, providing a rationale for developing FLI1 inhibitors for breast cancer treatment. (PMID: 26156017)
19. SLFN11 plays a role as a transcriptional target of EWS-FLI1 and is a determinant of drug response in Ewing sarcoma. (PMID: 25779942)
20. Fli1 is epigenetically suppressed and is a potential predisposing factor in the pathogenesis of systemic sclerosis. (Review) (PMID: 26055516)
21. The erythrocyte lineage enforces exclusivity through upregulation of EKLF and its lineage-specific cytokine receptor (EpoR) while inhibiting both FLI-1 and the receptor TpoR (also known as MPL) for the opposing megakaryocyte lineage. (PMID: 26159733)
22. Mutations in FLI1 are associated with Paris-Trousseau thrombocytopenia. (PMID: 26316623)
23. Fli-1 expression gradually increases in parallel with disease progression. (PMID: 26305602)
24. Simultaneous downregulation of KLF5 and Fli1 is a key feature underlying systemic sclerosis. (PMID: 25504335)
25. Endothelial CCN1 downregulation, at least partially due to Fli1 deficiency, may contribute to the development of digital ulcers in systemic sclerosis patients. (PMID: 25421497)
26. Bosentan increases DNA binding of Fli1 and suppresses type I collagen expression in systemic sclerosis fibroblasts. (PMID: 24708674)
27. The similarity between the phenotypes of EWS/FLI1- and EWS siRNA-transfected HeLa cells suggests that inhibition of EWS is the key mechanism for the induction of midzone defects. (PMID: 25483190)
28. FLI1 levels are reduced in human breast cancer samples and cell lines, and FLI1 expression is correlated with breast cancer cellular growth, migration, and invasion as well as altered gene expression. (PMID: 25379017)
29. p16 and potentially Fli-1 may be useful in assigning growth phase for cutaneous melanomas. (PMID: 25062258)
30. Overexpression of FLI1 is intimately related to malignant phenotypes and poor clinical outcome in epithelial ovarian cancer. (PMID: 24923303)
31. Fli1 binds to the CXCL5 promoter, and its gene silencing significantly suppresses CXCL5 mRNA expression in human dermal microvascular endothelial cells. (PMID: 24292093)
32. FLI1 expression is reported in epithelioid sarcomas. (PMID: 24072183)
33. Fli1 and CTGF are important mediators of the fibrogenic actions of adenosine. (PMID: 23663495)
34. Under quiescent conditions, Fli1 recruits HDAC1/p300 to the COL1A2 promoter and suppresses the expression of the COL1A2 gene by chromatin remodeling through histone deacetylation. (PMID: 24058639)
35. The confirmation that merkel cell carcinoma (MCC) is devoid of the EWS/FLI-1 rearrangement fills a gap in the literature. (PMID: 23165331)
36. Overexpression of the ETS-related transcription factor ETV1 can initiate neoplastic transformation of the prostate. (PMID: 23774214)
37. Alterations in FLI1 and RUNX1 may be common in patients with platelet dense granule secretion defects and mild thrombocytopenia. (PMID: 24100448)
38. Research suggests a novel function for Fli-1 in T cell development and leukemogenesis. (PMID: 23667468)
39. Podoplanin and Fli-1 immunohistochemistry may be useful in distinguishing atypical fibroxanthoma from angiosarcoma. (PMID: 23518636)
40. Ciprofloxacin exhibits antifibrotic actions in systemic sclerosis dermal and lung fibroblasts through downregulation of Dnmt1 and upregulation of Fli1. (PMID: 23041765)
41. In 5q- syndrome, but not Diamond-Blackfan anemia, blood and bone marrow mononuclear cells exhibit high Fli1 mRNA levels. This protects megakaryocytic cells from ribosomal stress and enables effective, albeit dysplastic, megakaryopoiesis. (PMID: 22965552)
42. SNP array and phenotype correlation data do not support the traditional view that FLI1 deletion is the cause of thrombocytopenia in Jacobsen syndrome. (PMID: 22887642)
43. Research has demonstrated that transcriptional activation of PRKCB is directly regulated by the chimeric fusion oncogene EWSR1-FLI1, which drives Ewing sarcoma growth. (PMID: 22930730)
44. FLI1 is a novel ETS transcription factor involved in gene fusions in prostate cancer, and intratumor genetic heterogeneity of ETS rearrangements can occasionally be found in index primary tumors. (PMID: 22081504)
45. There are no differences in the distribution of immunohistochemical reactivity for CD31, CD34, D2-40, or FLI1 between AIDS-related and non-AIDS-related Kaposi sarcoma (KS) or between nodular- and patch/plaque-stage KS. (PMID: 22372906)
46. Expression of FLI-1, ELF-1, and GABP activates the PF4 promoter in HepG2 cells. (PMID: 21931859)
47. Research has demonstrated an association between FLI1 and susceptibility to cutaneous leishmaniasis (CL) caused by L. braziliensis. (PMID: 21633373)
48. FLI1 expression is frequently abnormal and prognostically adverse in acute myeloid leukemia. (PMID: 21917756)
49. Research suggests a role for Fli1 as a negative regulator of the estrogen receptor alpha gene in dermal fibroblasts. (PMID: 21451544)
50. In SSc fibroblasts, c-Abl is an upstream regulator of the profibrotic PKCdelta/phospho-Fli-1 pathway, inducing PKCdelta nuclear localization. (PMID: 21321929)

These findings highlight the multifaceted role of FLI1 in various biological processes and its potential as a therapeutic target for a range of diseases.